IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern

Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to mitigate these challenges, but neutralization escape remains a major challenge and alternative strategies are needed. Here we present two anti-SARS-CoV-2 spike binding antibodies, one Class 1 and one Class 4, selected from our non-immune human single-chain variable fragment (scFv) phage library, that are engineered into four, fully-human IgG-like bispecific antibodies (BsAb). Prophylaxis of hACE2 mice and post-infection treatment of golden hamsters demonstrates the efficacy of the monospecific antibodies against the original Wuhan strain, while promising in vitro results with the BsAbs demonstrate enhanced binding and distinct synergistic effects on neutralizing activity against circulating variants of concern. In particular, one BsAb engineered in a tandem scFv-Fc configuration shows synergistic neutralization activity against several variants of concern including B.1.617.2. This work provides evidence that synergistic neutralization can be achieved using a BsAb scaffold, and serves as a foundation for the future development of broadly reactive BsAbs against emerging variants of concern.
The rationale for this cocktail Ab approach is clearly illustrated when comparing the efficacy and success of Lilly’s monotherapy bamlanivimab (LY-CoV555) and Regeneron’s combination therapy of casirivimab (REGN10933) with imdevimab (REGN10987), both of which were granted Emergency Use Authorization (EUA) in late 2020. As a monotherapy, bamlanivimab and casirivimab display weakness to B.1.351 (Beta); however, when casirivimab is administered in combination with imdevimab, high therapeutic efficacy is maintained. As bamlanivimab was originally administered as a monotherapy, the sensitivity to the B.1.351 strain lead to an increased risk of treatment failure and therefore the FDA revoked bamlanivimab’s monotherapy EUA in April 2021. To counter this, Lilly developed a second mAb (etesevimab, LY-CoV016) to be used in combination with bamlanivimab and was able to regain EUA approval for the combination therapy. In addition to the therapeutic benefits of combination therapies, AstraZeneca recently announced preliminary phase III results demonstrating that prophylactic administration of tixagevimab (AZD8895) with casirivimab (AZD1081) significantly reduced the incidence of symptomatic COVID-19.

Specific antibodies (BsAb) combine the antigen binding domains from two mAbs onto one framework, maintaining the advantage over the emergence of escape mutants without the need to produce two separate mAbs for cocktail therapy. BsAbs are classified into one of two categories, IgG-like or non-IgG like. IgG-like BsAbs provide rapid biodistribution and organ penetration. However, their size and lack of an Fc region allows them to be easily targeted and neutralize through one of the additional mechanisms using a spike shedding experiment similar to that developed by Wee et al. 29T3 cells were transduced to constitutively express the SARS-CoV-2 spike on the cell surface and as shown in Fig. 1D, treatment of these cells with Ab 12 leads to decreased levels of surface-bound antibody over time, suggesting that Ab 12 treatment leads to the loss of surface spike molecules. Though antibody-induced endocytosis potentially contributes to the decreased cell surface antibody detected, a time-dependent increase in the concentration of S1 in the supernatant following treatment with Ab 12 is observed (Fig. 1E), providing evidence that Ab 12 triggers the premature and irreversible shedding of the S1 domain. As these two antibodies have been demonstrated to target non-overlapping epitopes and utilize varying mechanisms of neutralization, Ab 12 and Ab 2-7 were chosen for further evaluation and engineering.

**Results**

**Discovery and in vitro characterization of Ab 12 and 2-7**

The Marasco Lab previously generated a 27-billion-member naïve phage library via random assembly of heavy and light chain variable genes isolated from peripheral blood of 57 healthy donors. Using this library, a phage panning campaign was completed using SARS-CoV-2 S1 and the receptor binding domain (RBD), leading to the discovery of anti-SARS-CoV-2 RBD antibodies Ab 12 and Ab 2-7. Kinetic parameters for the monovalent fragments of Ab 12 (Fab) and Ab 2-7 (scFv) were measured via biolayer interferometry (BLI) and both had nanomolar affinity to the SARS-CoV-2 RBD (Supplementary Fig. 1A, B). Initial epitope binning was performed with the bivalent scFv-Fcs via competition with ACE2 and CR3022, as these two proteins have been demonstrated to bind opposite ends of the RBD. This screening revealed that while both Ab 12 and Ab 2-7 block ACE2 binding, only Ab 2-7 inhibited CR3022 binding to the RBD (Fig. 1A). In addition to competing with both ACE2 and CR3022, Ab 2-7 binds the Tor2 spike protein, a SARS-CoV strain isolated in Toronto circa 2003, indicating that it likely binds the more conserved RBD core (Fig. 1B).

Ab 12 and Ab 2-7 were next tested for SARS-CoV-2 neutralization via plaque reduction neutralization tests (PRNT) and recombinant nLu viruses. Both Abs neutralized SARS-CoV-2, although Ab 12 scFv-Fc was significantly more potent with an IC50 of 0.86 nM compared to 47.36 nM for Ab 2-7 in PRNT assays (Fig. 1C). While blockade of RBD-ACE2 interactions is the most commonly observed mechanism of antibody neutralization, other mechanisms have also been identified, including destabilization of the pre-fusion spike trimer, premature shedding of the S1 domain and conversion to the post-fusion conformation, and restricting access to the post-fusion conformational state. Among these, destabilization of the spike trimer and premature shedding of the S1 domain are preferred methods of neutralization, as both of these are irreversible and permanently disable the spike protein from binding ACE2. Conversely, blockade of ACE2 binding and locking the spike in the pre-fusion conformation are transient mechanisms that are reversed upon antibody dissociation. Having demonstrated that our antibodies block ACE2 binding to the RBD, we looked to determine if our antibodies are able to neutralize through one of the additional mechanisms using a spike shedding experiment similar to that developed by Wee et al.

Structural analysis of Ab 12 and Ab 2-7

To examine the mode of binding of Ab 2-7 to SARS-CoV-2 spike, we initiated structural studies by electron microscopy (EM). We obtained two high-resolution 3D cryo-EM reconstructions of Ab 2-7 scFv complexed with SARS-CoV-2 S D614G: one with two scFvs bound to a spike trimer, and the other with three scFvs bound (3.4 Å and 3.0 Å respectively, Supplementary Fig. 2, Fig. 2A, B). We also determined a structure of this variant in the absence of any ligands to facilitate comparison with the scFv-bound structures (3.0 Å, Supplementary Fig. 2), Local refinement of a masked region comprising the spike RBD, NTD, and Ab 2-7 scFv improved the quality of the 3D reconstruction for the 3-scFv-bound structure (Supplementary Fig. 3, Fig. 2C), allowing us to conclude that Ab 2-7 binds to the non-receptor binding motif (RBM) core of the RBD using a mix of heavy and light chain interactions from CDR H3 and L1-L3 as well as two residues from the framework region of the light chain. The interface features a dozen hydrogen bonds, five π-π stacking interactions, and 829 Å of buried surface area (Fig. 2D) with the π-π interactions clustered around three residues in the non-RBM core of the spike RBD: Y369, F377, and P384. Comparison of the three structures (zero, two and three Ab 2-7 scFv bound) sheds light on the mechanism of Ab 2-7 scFv binding to the spike trimer. The structure of spike trimer bound to two Ab 2-7 scFv molecules shows the third unbound RBD in the up conformation. Superposition with the apo-spike structure reveals that Ab 2-7 scFv would clash with the RBD of the neighboring spike protomer if it were in the down-conformation and therefore cannot fully engage its...
binding epitope until at least two RBDS are in the up conformation (Fig. 3A top inset). Once bound, Ab 2-7 scFv prevents the RBD from accessing the down conformation. Furthermore, superposition of Fab constant regions (CHI/CL) onto the Ab 2-7 scFv structure indicates that the CHI/CL domains would clash with the NTD of the neighboring protomer (Fig. 3A bottom inset). Ab 2-7 scFv thus binds to the spike in a manner that would be inaccessible to its Fab form.

Cryo-EM structures were also solved for the Ab 12 Fab in complex with the ectodomain of the SARS-CoV-2 spike at 3.6 Å resolution. The 3D classification of the particles showed the presence of spike trimers with either one or two Ab 12 Fabs bound at once. Similar to Ab 2-7, Ab 12 also targets the RBD in the up-configuration (Fig. 2E), however Ab 12 targets the RBM, recognizing an epitope centered over the RBD saddle. Ab 12 also targets the RBD in the up-conformation with either one or two Ab 12 Fabs bound at once. Similar to Ab 2-7, Ab 12 targets the RBM, recognizing an epitope centered over the RBD saddle.

**Fig. 1 | Biochemical characterization of Ab 12 and Ab 2-7 scFvs.** 
A Competition matrix showing percent blockade of CR3022 and ACE2 binding to SARS-CoV-2 RBD. B Antibody binding at 2 μg/ml was measured by ELISA against Tor2 SARS-CoV spike (Toronto, 2003), n = 2 biologically independent samples and the mean is presented. C PRNT neutralization assays performed with SARS-CoV-2 (isolate USA-WAI/2020) demonstrate that Ab 12 is the more potent of the two scFvs. Samples were tested as 3 biologically independent samples with 3 technical replicates per sample and the data is presented as the mean with standard deviation. D FACS based measurement of spike shedding induced by binding of Ab 12, Ab 2-7, CR3022 IgG, and soACE2 at 37°C. A decrease in median fluorescence indicates an increase in spike shedding whereas an increase in fluorescence indicates minimal shedding is observed (n = 2 biologically independent samples with the mean represented). E Western blot detecting shed S1 in supernatant from Ab 12 IgG spike shedding experiment confirming decreasing fluorescence is at least partially a result of shedding. Experiment was repeated once and representative data is presented. Source data are provided as a Source Data file.

**In vivo neutralization in Syrian golden hamsters**
The in vivo biological activity of these mAbs was next tested in Syrian golden hamsters, a model for severe COVID-19. Consistent with in vitro data, Ab 12 treatment 1 day post intranasal viral challenge resulted in a significant decrease (~500-fold) in the lung viral titers compared to untreated animals (Fig. 4A). Pathological analysis of the lung tissues showed that compared to control-treated animals, Ab 12 treatment leads to marked reduction in consolidation, smaller foci of infiltration, and minimal perivascular cuffing (Fig. 4B, S6). In contrast, Ab 2-7 scFv-Fc treatment resulted in only a 5-fold decrease in titer compared to control treated animals (Fig. 4A). Pathologic scoring demonstrated that Ab 2-7 treatment did not significantly reduce consolidation or inflammatory infiltration although a modest decrease in the number of inflammatory cells in the airways and in severity of the perivascular cuffing was observed (Fig. 4B, S6). Thus, while Ab 12 IgG showed therapeutic benefit when used alone, only modest anti-viral effects were seen with Ab 2-7 scFv-Fc.

**Development and characterization of bispecific antibodies**
Coronaviruses are positive-sense, single-stranded RNA viruses that are characterized by high mutation rates. The mutagenic capability of a virus depends upon several factors, including the fidelity of viral enzymes that replicate nucleic acids and these mutations drive viral evolution and genome variability. While many naturally occurring mutations do not have a significant impact on viral fitness, some mutations can have a detrimental effect leading to viral extinction, and other more rare mutations promote viral evolution and escape from
anti-viral therapies. This is demonstrated by the diversity of variants circulating today and the primary challenge to mAb therapies are mutations that arise in the spike protein within the mAb binding site as a result of inaccuracies during viral replication combined with immune pressure\textsuperscript{26,34–36}. To counter the emergence of these mutations, we used Ab 12 and Ab 2-7 to develop a series of BsAbs targeting their spatially discrete epitopes on the RBD, with the intent of raising the threshold required for SARS-CoV-2 variants of concern to undergo neutralization escape. Four BsAbs were developed, two are IgG fusions, using the more potent Ab 12 as the IgG scaffold with an Ab 2-7 scFv fused to the C-terminus of either the heavy or light chain constant regions via a flexible linker. Two additional BsAbs were developed using both orientations of a tandem scFv arrangement, fused to an IgG Fc via an CD8 hinge domain (Fig. 5A, S7).

As with the monospecific Abs, in vitro neutralization activity of these BsAbs was tested in PRNT assays. While the IgG fusion BsAbs show a shift to the left in the dose–response curve compared to the parental mixture and individual antibodies, the tandem scFv BsAbs display a more subtle shift in efficacy (Fig. 5B, C). To further investigate the prophylactic potential of the BsAbs, we tested the constructs in vitro and in vivo using a mouse-adapted SARS-CoV-2 virus\textsuperscript{37}. The RBD of the mouse-adapted strain has two mutations that allow for

---

**Fig. 2 | High resolution cryo-EM structure of Ab 2-7 scFv and Ab 12 Fab complexed SARS-CoV-2 S D614G.** A Side and (B) top views of a composite 3D cryo-EM reconstruction of Ab 2-7 scFvs bound to the receptor binding domains of SARS-CoV-2 spike ectodomains at 3.0 Å resolution. Individual spike protein protomers are colored red, blue and green. The heavy chain of Ab 2-7 scFv is colored yellow, the light chain is colored tan. C Locally refined 3D cryo-EM reconstruction of antibody binding interface. D Atomic model of the binding interface between Ab 2-7 scFv and the spike RBD. E Side view of 3D EM reconstruction of Ab 12 Fab (purple) bound to the RBD of SARS-CoV-2 spike ectodomain. Overlay of the Ab 2-7 and Ab 12 structures demonstrates that the two antibodies target spatially discrete, non-overlapping epitopes (insert, with the Ab 12 cryo-EM reconstruction shown in gray).
binding to mouse ACE2 and these mutations lie on the edge of the Ab 12 binding site (Supplementary Fig. 8A). Against this mouse-adapted strain, Ab 12 IgG showed an approximately one log loss of neutralization activity compared to Ab 12 scFv-Fc but no difference in neutralization activity between these Ab 12 formats was seen against the WT Wuhan strain (Supplementary Fig. 8B). In vivo against the mouse-adapted strain, the HC Fusion displayed the greatest potency among the BsAbs and was superior to the parental Ab 12 IgG monotherapy, however the two Ab cocktail therapies displayed the greatest potency overall (Supplementary Fig. 9A). To determine if the RBD mutations Q498Y and P499T in the mouse-adapted strain negatively affected the efficacy of our Abs, we chose one of the most potent overall treatments (Ab 12 + Ab 2-7 scFv-Fcs) and the most potent BsAb (HC Fusion) for testing in a transgenic humanACE2 mice using WT SARS-CoV-2 virus. Supplementary Fig. 9B demonstrates that prophylactic treatment with either the scFv-Fc combination or HC Fusion leads to viral titers below the limit of detection, except for one mouse treated at the lowest concentration of BsAb, confirming that the results seen in the mouse-adapted virus for these two treatments were likely skewed by the RBD mutations.

**Fig. 3** | Ab 2-7 can only bind as an scFv and Ab 12 competes with ACE2. A Cryo-EM reconstruction of unbound S-D614G with one RBD in the up conformation (3.0 Å). Coloring is the same as in Fig. 2. The inset at the top right shows that Ab 2-7 would clash with the “down” RBD of the neighboring spike protomer (green cryo-EM reconstruction, filtered to 6 Å). The inset below shows Ab 2-7 modeled as a Fab, wherein the CH region would clash with the spike NTD (blue cryo-EM reconstruction, filtered to 6 Å). Clashes are indicated as white arrows. B Overlay of ACE2 bound to the RBD confirms that Ab 12 directly competes for the receptor binding motif (RBM). Ab 2-7 binds the conserved RBD core and does not directly compete with ACE2. Clashes are indicated as white arrows.

**Binding analysis of mono- and bi-specific antibodies to circulating SARS-CoV-2 variants.** The D614G spike mutation increases the stability of the spike protein and favors the RBD to maintain the up conformation, leading to increased ACE2 accessibility and thereby infectivity, allowing it to briefly become the predominant strain circulating worldwide45–47. Using this mutation as a template, the first variant of concern, B.1.1.7 (Alpha), soon emerged and as of December 2021, four additional variants of concern have been identified, B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron), each containing a unique combination of spike mutations resulting in varying levels serum and monoclonal antibody evasion48–50.

To determine the effect of these mutations on the affinity of our mono- and bi-specific Abs, binding experiments were conducted using...
neutralizing antibodies targeting adjacent epitopes remain potent. However, antibodies targeting epitopes that include N501, however, B.1.1.7 has demonstrated the ability to reduce the potency of neutralized and convalescent individuals, the RBD mutation (N501Y) in plasma neutralization and reduce the affinity of both bamlanivimab (Class 2) and casirivimab (Class 1).

Conversely, the B.1.351, P.1, and B.1.1.529 lineages contain three RBD perturbations generated by the N501Y mutation seen in B.1.1.7. Constructs for the B.1.1.7 spike compared to the WT spike, suggesting that leading with the Ab 2-7 scFv in the tandem BsAb provides better access to both antibody binding sites compared to the reverse tandem orientation, enabling enhanced binding. Combined with the lack of binding seen in Fig. 6A across all mono- and BsAbs, the decision was made not to test B.1.1.529 neutralization in vitro.

**In vitro neutralization of circulating SARS-CoV-2 variants of concern**

In vitro neutralization experiments using the D614G, B.1.1.7, P.1, B.1.351, and B.1.617.2 variants were performed next. Similar to the spike binding experiments, the D614G and B.1.1.7 variants showed sufficient reduction in binding of the BsAbs and ACE2 blockade potential likely arises from the increased avidity seen with the tetravalent bispecifics at saturating conditions compared to sub-saturating conditions used in the binding assay. This is further supported by the fact that even under saturating conditions, bivalent Ab 12 struggles to bind the variant RBDs at high enough levels to efficiently block ACE2 binding, and both Ab 12 and Ab 2-7 demonstrate minimal blockade of the B.1.1.529 RBD (Fig. 6B).

Overall, our antibodies exhibited relatively weak binding to the majority of the variants tested, with Ab 12 and the IgG fusions exhibiting near complete loss of binding. The exception to this is the Ab 2-7/Ab 12 tandem scFv-Fc construct that demonstrated only moderate loss of binding to all variants except for B.1.1.529 (Fig. 6A). This suggests that leading with the Ab 2-7 scFv in the tandem BsAb provides better access to both antibody binding sites compared to the reverse tandem orientation, enabling enhanced binding. Combined with the lack of binding seen in Fig. 6A across all mono- and BsAbs, the decision was made not to test B.1.1.529 neutralization in vitro.
comparable neutralization patterns to that of the WT strain shown previously in Figs. 1 and 5, with the BsAb showing the greatest neutralization. Ab 12 falling in the middle, and Ab 2-7 showing the weakest neutralization (Fig. 7A, B). However, the efficacy of these two mAbs changed markedly with respect to the variants of concern. Ab 12 neutralization decreased significantly against P.1 and B.1.351, and is completely abolished against the B.1.617.2 strain. In contrast, Ab 2-7 showed a marked gain in neutralization activity against these same three strains. This is further reflected when looking at cocktail therapies against the B.1.351 and B.1.617.2 variants, as the Ab mixture generally performs at a level similar to Ab 2-7, suggesting that the inclusion of Ab 12 in the mixture is providing minimal benefit (Fig. 7C–E, Supplementary Table 3).

The BsAb advantage over cocktails is seen in the neutralization of B.1.351, as both IgG fusions and the Ab 2-7/Ab 12 tandem scFv-Fc constructs display moderate improvements in neutralization compared to a combination of parental Abs (Fig. 7D). Furthermore, the strength of the Ab 2-7/Ab 12 tandem scFv-Fc construct is further exemplified against B.1.617.2. As shown in Fig. 7E, while Ab 12 and both IgG fusions possess no or weak neutralization ability respectively and the Ab 12/Ab 2-7 tandem mirrors that of Ab 2-7 alone, the Ab 2-7/Ab 12 tandem scFv-Fc tandem displays potent neutralization with a circa 12-fold improvement compared to the combination therapy. To evaluate if the increased neutralization of these BsAb constructs was a result of synergy or simply an additive effect of the two parental components, the neutralization curves in Fig. 6 were analyzed in CompuSyn and Combination Index (CI) scores were calculated at the IC_{50} and IC_{95}. As shown in Supplementary Fig. 10, the BsAbs and combination therapies mostly display synergistic (CI<1) activity against the tested variants with the Ab 2-7/Ab 12 Tandem scFv-Fc construct often displaying the greatest synergy.

Discussion
In this manuscript we characterize two neutralizing anti-SARS-CoV-2 antibodies that target non-overlapping epitopes with different binding and therapeutic efficacies both in vitro and in vivo. Class 1 Ab 12 was found to be more potent than Ab 2-7 in vitro and in vivo and triggers the spike protein to undergo an irreversible switch into the post-fusion conformation whereas Class 4 Ab 2-7 targets the conserved RBD core domain, binds with higher affinity and does not trigger spike shedding. To broaden the anti-viral properties these two mAbs, they were engineered into a series of four tetravalent, IgG-like BsAbs. The outcome of both in vitro and in vivo studies demonstrated that the format and orientation of these two binding sites were important for breadth of neutralization and in vivo protection. Compared to each mAb alone or cocktails of the mAbs in different formats, the BsAbs generally showed enhanced neutralization activity against WT and tested variants of concern (Fig. 5, 7). The Ab 2-7/Ab 12 tandem BsAb showed the most potent in vitro neutralization against WT and all variants of concern that were studied and was 12-fold more potent than the other BsAbs or the antibody cocktails against B.1.617.2.

Antibody combinations targeting multiple epitopes are becoming common practice for anti-viral therapies. The first COVID-19 combination therapies were developed by Regeneron and Lilly, with AstraZeneca’s recently completing clinical trials. The Class 1 & 2 antibody pairs developed by Lilly (etesevimab and bamlanivimab) and AstraZeneca (tixagevimab and cilgavimab) both target the ACE2 binding interface13–15. Conversely, like the BsAbs described in this work, Regeneron’s pair consists of an RBM directed Class 1 (casirivimab) and an RBD core targeting Class 4 (imdevimab) Ab16. While there is a clear neutralization benefit to targeting two regions within the ACE2 binding motif, this region is prone to the development of mutations that lead to antibody evasion like those seen at residues L452, E484, and N50155,57. The importance of epitope selection is further exemplified by the ineffectiveness of Lilly’s combination therapy against the P.1 and B.1.351 variants, and the subsequent distribution halt only months after receiving EUA, however distribution has since been resumed in selected states16. Ab 12 is comparable to bamlanivimab and casirivimab as it is a potent neutralizer, though sensitive to the RBD mutations seen in the B.1.351, P.1, and B.1.617.2 variants. Ab 12 was also sensitive to the Q498Y and P499T mutations in the mouse-adapted strain but these mutations are rarely seen in circulating strains16,17. Ab 2-7 targets the
neutralization against B.1.351, P.1 and B.1.617.2 (Fig. 7). These results suggest that the unbound arm58. As seen with the original Wuhan SARS-CoV-2 the linked nature of the binding domains, BsAbs are known to enhance neutralization.

Developed four BsAbs using three different scaffolds. Due to the L452/T478 mutations in B.1.617.2 increases their sensitivity to Ab 2-7 suggests that the K417/E484 mutations in the B.1.351 and P.1 strains, and associated and artificial increasing the localized concentration of the unbound arm58. As seen with the original Wuhan SARS-CoV-2 the linked nature of the binding domains, BsAbs are known to enhance neutralization.

Fig. 6 | BLI binding and competition analysis for mono- and bispecific constructs with various variant spike/RBD proteins. A AHC sensors were loaded with anti-SARS-CoV-2 mono- and bispecific Abs and then dipped into wells containing different Spike variants. Amplitude of the binding signal for each variant was normalized to that Ab format against the Wuhan spike. Though the parental Abs, IgG, and Ab 12/Ab 2.7 tandem BsAbs exhibit marginal affinity to the variants tested, Ab 2-7/Ab 12 constantly binds at a greater level than either of the parental Abs, indicating a synergistic binding pattern. B Competition with ACE2 for binding to Wuhan, B.1.351, B.1.617.2, and B.1.1.529 RBDs was performed with biotinylated RBD proteins and soluble ACE2. Though our BsAbs weakly bind mutant spikes at low concentration, at high concentrations they are able to effectively block ACE2 binding to the RBD. Two chimeric antibodies from Acro Biosystems were used as experimental controls, as both are cross-reactive but only AM122 has been demonstrated to compete with ACE2 binding. The percent binding experiment was performed in triplicate and mean values are shown. Competition was performed as a single experiment. Source data are provided as a Source Data file.

to further enhance the synergistic effect of these two mAbs, we developed four BsAbs using three different scaffolds. Due to the linked nature of the binding domains, BsAbs are known to enhance the affinity of the component mAbs by sterically hindering disassociation and artificially increasing the localized concentration of the unbound arm58. As seen with the original Wuhan SARS-CoV-2 strain, the BsAbs displayed moderate improvements when tested against the D614G, B.1.1.7, and P.1 variants compared to the mono-Ab therapies and less improvement over the combination cocktail therapies of the parental mAbs (Supplementary Table 3). The exception to this was the Ab 2-7/Ab 12 tandem scFv-Fc which displayed a 3.7-fold improvement compared to the scFv-Fc combination against the P.1 variant. The synergistic effect was even more pronounced with this construct against the B.1.351 and B.1.617.2 strains, with 13- and 12-fold improvement compared to the cocktail respectively. Importantly, the BsAb is only circa 2.1-fold less potent against the B.1.351 variant compared to the Regeneron cocktail which is 9.1-fold less potent59. The ability of the Ab 2-7/Ab 12 tandem scFv-Fc to maintain superior neutralization compared to the other BsAbs is likely due to the orientation of the binding epitopes on the RBD. The reverse orientation tandem scFv-Fc (Ab 12/Ab 2-7) is not able to enact similar synergy as the CI values are higher and the neutralization curves tend to be similar or weaker to that of the combination against the P.1 and B.1.617.2 strains. This suggests that in the Ab 12/Ab 2-7 format, the tandem scFvs are not acting in concert, rather they are binding independent of each other, thus they simply resemble their parental components. The enhanced binding and synergistic neutralization is strong against the B.1.617.2 variant, as Ab 12 alone possesses no neutralization capability, due to decreased binding similar to that seen with bamlanivimab7. Both IgG fusions also display minimal neutralization against this variant, suggesting that the paratopes of the Ab 2-7 scFvs displayed on these fusions are not oriented properly for synergistic binding and enhanced neutralization. In the case of the Ab 2-7/Ab 12 tandem scFv-Fc, the Ab 2-7 domain is able to provide an anchor point for Ab 12, allowing it to
overcome its decreased binding efficacy to the various mutant strains, and enact potent synergistic neutralization.

To date, numerous laboratories have developed anti-SARS-CoV-2BsAbs. Similar to the CoV-X2BsAb developed by De Gasparo et al., our BsAbs are fully human Ig-like molecules that display potent neutralization against a wide range of SARS-CoV-2 variants. Biochemical characterization of the lead Ab 2-7/12 tandem scFv-Fc and the other BsAbs constructs demonstrate properties suitable for clinical development, including efficient expression and assembly, minimal aggregation, and comparable thermostability to the parental constructs (Supplementary Fig. 6A–C). Additionally, they maintain binding to the neonatal Fc receptor (FcRn), an important component to IgG recycling and extending serum half-life in vivo (Supplementary Fig. 7E). Li et al. also used a pair of non-competing antibodies to develop a dual-variable domain immunoglobulin (DVD-Ig) and IgG-scFv BsAbs, the latter of which is comparable to our HC Fusion. Their lead construct displayed similar potency against live virus, however the epitopes targeted by their Ab pair provided greater breadth of neutralization for the IgG-scFv construct. Both Cho et al. and Ku et al. first identified non-competing mAb pairs that displayed limited sensitivity to the immune evading mutations to develop a series of DVD-Ig bispecifics. From this, they demonstrated that their BsAbs were able to crosslink adjacent spike proteins, a novel mechanism of neutralization that is not accessible by typical mAbs. A major difference between CoV-X2 and the other BsAbs discussed here is that the CoV-X2 construct maintains the two binding site structure of conventional mAbs, whereas our constructs introduce two additional binding sites resulting in a tetravalent molecule allowing for increased avidity, inter-spike binding, and enhanced neutralization potential.

As the SARS-CoV-2 virus continues to evolve, innovative strategies are urgently needed to optimize Ab potency and breadth of neutralization. The commercially developed Abs described previously were derived from convalescent COVID-19 patients (Lilly/AstraZeneca) or from immunization of engineered mice (Regeneron). In contrast, our antibodies were discovered via panning of a non-immune phage library that has not undergone affinity maturation for SARS-CoV-2 spike. We previously used this pipeline during the SARS-CoV and MERS campaigns to develop therapeutic Abs and cocktails, thus demonstrating that these non-immune Ab libraries created 23 years ago contain Abs that recognize a heterogenous group of CoV spike proteins. Interestingly, while Ab 12 activity decreased significantly against P.1 and B.1.351 strains, and was completely abolished against the B.1.617.2 strain, Ab 2-7 showed a marked gain in neutralization activity against these same three strains. Deep mutational scanning of both the RBD epitopes and the Ab binding paratopes can be performed to further interrogate the binding interaction of our antibodies, allowing for the identification of potential escape mutants and providing a means for the engineering of affinity matured Abs with enhanced neutralization capabilities. Tackling this problem is not trivial for a BsAb since variable effects on synergy or antagonism may be seen; however, the Ab 2-7/Ab 12 tandem scFv-Fc exhibits synergistic properties and demonstrates potent neutralization against the currently tested variants of concern. The engineering and development of symmetric BsAbs is a rapidly growing field with significant therapeutic and manufacturing benefits. Although the tandem scFv-Fcs developed in this work provide evidence that synergistic neutralization can be achieved, further optimization can be performed to increase their breadth of binding and potency. Accordingly, they are an important steppingstone and serve as a foundation for the future development of a unique scaffold for broadly reactive BsAbs against emerging variants of concern.

**Methods**

**Phage panning**

Peripheral B cells from 57 healthy donors were used to create two, non-immunized scFv-phage libraries totaling 2.7×10^10 members. 1.66×10^3 pfu of scFv-phage from each library was combined and used to perform 3 rounds of panning against SARS-CoV-2 S1 protein (Sino Biologicals) or SARS-CoV-2 RBD protein expressed in our lab. Briefly, SARS-CoV-2 RBD or S1 proteins were passively absorbed onto Nunc
MaxiSorp Immuno tubes (Thermo Fisher Scientific) overnight in PBS. Coated tubes were incubated with the phage library, followed by extensive PBS/PBS-T (PBS + 0.05% Tween-20) washes to remove non-specific phage. Bound phage were eluted with 100 mM triethylamine and neutralized with 1 M Tris-HCl, pH 7.5. The eluted phage solution was neutralized, amplified, and used for further selection or screening. SARS-CoV-2 S1 and RBD coating concentration was decreased in each round to increase the affinity of the enriched antibodies.

Screening of the enriched library was performed by selecting circa 1300 bacterial colonies from the 3rd round of panning and culturing them in individual wells in 96 well plates. Small-scale rescue was performed via VCS-M13 helper phage and the phage supernatant was used to screen via SARS-CoV-2 RBD or S1 coated ELISA plates. Positive wells were selected for colony PCR and subsequent sanger sequencing. Unique sequences were then cloned into the appropriate expression vector for further analysis.

BsAbs design
BsAbs were designed to utilize different functional formats of Abs 12 and 2-7. IgG fusions were built using Ab 12 IgG as the scaffold, with Ab 2-7 scFv genetically fused to the C terminus of the LC (CL fusion) or CH3 (IC fusion) domains via a flexible (G4S)5 or (G4S)2 linker respectively. Tandem scFv-Fc construct consists of two scFvs linked with a flexible (G4S)3 linker fused to a CD8 hinge – IgG1-Fc domains and was created in both orientations (Ab 12/Ab 2-7 and Ab 2-7/Ab 12).

Recombinant SARS-CoV-2 protein production
hACE2 (transOMIC) and SARS-CoV-2 RBD/S1 (Sino Biologics) cDNA were purchased and cloned into our mammalian expression vector. Stabilized SARS-CoV-2 spike trimer expressing plasmid was obtained through BEI and the HexaPro expression plasmid was a kind gift from Dr. Jason McLellan’s Lab (UT Austin). All proteins were expressed in the Exp293F system and cells were transiently transfected by ExpiFectamine 293 (all components purchased from Thermo Fisher Scientific) following the standard protocol. 4-5 days after transfection, supernatants were clarified and incubated with Ni-NTA resin (Qiagen) overnight at 4 °C. They were subsequently purified via gravity flow column and buffer exchanged by centrifugation in Amicon centrifugal filters. Avi tagged proteins were biotinylated by Avidity’s BirA biotinylation kit following standard protocols. Protein concentration was measured on a Nanodrop 1000 using the MW and extinction coefficients calculated on ExPASy’s ProtParam.

Antibody production
Antibodies were produced in Exp293F cells (Thermo Fisher Scientific catalog #A14635) using transiently transfected mammalian expression vectors following the standard ExpiFectamine293 protocol. The harvested supernatants were incubated with Protein A-Sepharose 4B resin (Invitrogen) overnight at 4 °C followed by purification via gravity flow columns (BioRad) and buffer exchanged by centrifugation in Amicon centrifugal filters. Protein concentration was measured on a Nanodrop 100 using the MW and extinction coefficients calculated on ExPASy’s ProtParam.

Biolayer interferometry (BLI) binding assays
All assays were performed in 96-well black plates on an Octet Red96 instrument (Sartorius) with shaking at 1000 RPM. Sensors (SA for kinetics, competition, and FcRn; AHC for variant spike binding) were first loaded with the ligand of interest, then transferred to wells containing the appropriate analyte diluted in PBST to determine koff, followed by wells containing only PBST to measure koff. For sensors that were used with multiple analytes, regeneration was performed by alternating cycles of 0.1 M glycine buffer pH 2.7 and PBST. All samples were made in PBST except for FcRn binding assay, which was prepared in PBS titrated to pH 6 with hydrochloric acid. Naked sensors or sensors loaded with an irrelevant protein were used as nonspecific binding controls. To enable accurate curve fitting, data preprocessing was performed using built-in functions of the Octet Data Analysis Software v10.0.0.5. First, nonspecific binding (reference wells) was subtracted from the dataset, followed by Y-axis alignment to the baseline, inter-step correction to remove step misalignments due to sensor artifacts, and Savitzky-Golay filtering to remove high-frequency noise. The Octet Data Analysis Software (v10.0.0.5) was then used for kinetic curve fitting of the processed data using a 1:1 binding and a global fit of the tested concentrations.

FACS S1 disassociation
FACS S1 disassociation assay was previously described in Wec et al. Briefly, 293T-Spike cells (293T-17 ATCC catalog #CRL-11268 transduced to stably express the SARS-CoV-2 spike) were washed, resuspended at 4E6 cells/ml in MACS buffer with 20 uM cycloheximide (MACS+) to inhibit protein synthesis, and aliquoted at 50 ul per well in a V bottom 96 well plate. Abs were diluted to 200 nM in MACS+ and both Ab dilution and cell plates were incubated separately at 37 °C for 15 min to equilibrate the plates. At the desired time points, 50 ul of Ab dilution was transferred to the corresponding well in the 96 well plate and mixed via pipetting. The plate was maintained at 37 °C during the entire time course. After the last time point, the cell plates were rapidly transferred to ice and quenched with ice cold MACS buffer. The plate was washed 2x with MACS buffer, followed by resuspension in anti-Hc-APC (BioLegend clone HP6017) at the manufacturer’s recommended concentration for 20 min at 4 °C. Cells were washed 3x with MACS buffer before fixation by 1% paraformaldehyde (Boston Bio Products). Cells were analyzed on a BD Canto II with HTS reader. Samples were run in duplicate.

Production of Ab 2-7 scFv for cryo-electron microscopy
A plasmid encoding for the Ab 2-7 single-chain Fv was transiently transfected into HEK293F cells (Thermo Fisher Scientific catalog #R79007). Six days after transfection, the medium was harvested, buffer exchanged, and concentrated, then passed over Nickle TAA affinity resin. Elution fractions containing Ab 2-7 scFv were pooled, concentrated, and further purified by size exclusion chromatography (Superdex 200, 2 mM Tris pH 8, 200 mM NaCl, 0.02% [w/v] sodium azide). Elution fractions containing monomeric, monodisperse Ab 2-7 scFv were pooled, concentrated, aliquoted, and flash frozen in liquid nitrogen.

Cryo-EM of Ab 2-7 complexed with SARS-CoV-2 S D614G
Purified Ab 2-7 scFv was mixed with purified SARS-CoV-2 S D614G (ExcellGene SA) at a molar ratio of 1:51 (Ab 2-7 to spike). Spike protein was purified by size exclusion prior to complex formation to remove soluble aggregates. The sample was incubated at room temperature for 30 min, deposited onto gold cryo-EM grids (UltroAuFoil 1.2/1.3), which had been plasma cleaned for 3 min using a Solarus 950 plasma cleaner (Gatan) with a 4:1 ratio of 02:H2. The excess protein sample was blotted away (Vitrobot filter paper; -3 force, 4 s blot time, 100% humidity, room temperature) before plunge freezing in liquid ethane (Vitrobot, ThermoFisher). Grids were screened for quality on a Talos F200C transmission electron microscope equipped with a Ceta 16 M detector (ThermoFisher). Grids that passed quality control were loaded onto a Titan Krios (ThermoFisher) operating at 300 kV, equipped with a K3 Detector (Gatan). The pixel size was 0.66 Å. Motion correction and CTF estimation were performed in WARP. Particle picking, 2D classification, 3D reconstruction and refinement were performed in cryoSPARC. Model building was performed iteratively using Coot, Isolute, and Phenix. A detailed description of image collection, processing and model quality is shown in Supplementary Figs. 2, 3.
Cryo-electron microscopy of the complex between SARS-CoV-2 S-D614G and Ab 12 Fab

0.5 mg of Prefusion-stabilized SARS-CoV-2 S-D614G was incubated with a 10-fold molar excess of Ab 12 Fab overnight. The complex was purified by size exclusion chromatography on a Superose 610/300 GL column and concentrated to 2 mg/ml. Electron microscopy grids were prepared by placing a 3 µl aliquot of the sample on 2/1-C-Bar grids (2/1-C-3T, Protocor Inc) glow discharged for 15 s on a Pelco glow discharge unit, and frozen by dipping in liquid ethane using a Vitrobot Mark IV device, after a 6-s blotting time (Whatman #1 filter paper). The grids were then clipped and transferred to the autoloder system of a Titan Krios G3 electron microscope (ThermoFisher Scientific) equipped with a K3 direct electron detector (Gatan Inc) at the end of a BioQuantum energy filter, using an energy slit of 20 eV. The microscope was operated with an accelerating voltage of 300 kV, a total electron dose of 50e/A². Grids were imaged at a magnification of 75kX, corresponding to a pixel size of 0.66 with the program EPU, under zero loss imaging, using a 20 eV window. Motion correction, CTF estimation, and particle picking were done with Warp. Extracted particles were exported to cryoSPARC-v2 (Structura Biotechnology Inc.) for 2D classification, ab initio 3D reconstruction, and refinement. CI symmetry was used during homogeneous refinement. Models were docked into the experimental EM density using Chimera and Phenix. One starting model was used: SARS-CoV-2 S with two RBDs in the “up” conformation (PDB ID 7KST, https://doi.org/10.1038/s41586-020-2852-1), and a homology model of Ab12 Fab that was generated using the SAbPred server.

Image processing for Ab 12

We collected 3979 images which were pre-processed using the program Warp, which does motion correction, followed by CTF estimation and particle picking using a machine learning algorithm. In this way, we ended up with 676,973 particles, which were transferred to the program cryosparc for further processing. The processing started with the use of a blob picker, followed by 2D classification to discard bad particles, followed by an ab initio reconstruction to produce a suitable volume for further refinement. For the ab initio we requested three different classes, using a maximum of 20,000 particles each, and imposing 3-fold symmetry.

Refinement for each of the ab initio classes was done without imposing any symmetry and using all the particles remaining in the dataset. The reconstruction that was deemed to be the best one by appearance was further used to produce three different classes by heterogeneous refinement, using the volumes produced by the homogeneous refinements. The class that gave the best reconstruction by appearance was then used for non-uniform reconstruction. This reconstruction was re-projected and the projections used to search for more particles using the template picker. In this way, we ended up with a total of 293,289 particles. With these new particles, we ran a homogeneous refinement using the last reconstruction for alignment, followed by a cycle of heterogeneous refinement, and then a non-uniform refinement. We were aiming to improve the visualization of the details in the Fab regions. The final reconstruction has a total of 131,548 particles.

Plaque reduction neutralization test

A series of 10 half-log dilutions was prepared in triplicate for each antibody or antibody mixture in Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco). Each dilution was incubated at 37 °C and 5% CO₂ for 1 hour with an equal volume of 1000 plaque forming units/ml (PFU/ml) of SARS-CoV-2 (isolate USA-WAI-2020), diluted in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) containing 2% fetal bovine serum (Gibco) and antibiotic-antimycotic (Gibco). Controls included DMEM containing 2% fetal bovine serum and antibiotic-antimycotic only as a negative control, 1000 PFU/ml SARS-CoV-2 incubated with DPBS, and 1000 PFU/ml SARS-CoV-2 incubated with DMEM. Two hundred microliters of each dilution or control were added to confluent monolayers of Vero E6 cells (BEI Resources catalog #NR-596) in triplicate and incubated for 1 hour at 37 °C and 5% CO₂. The plates were gently rocked every 5–10 min to prevent monolayer drying. The monolayers were then overlaid with a 1:1 mixture of 2.5% Avicel® RC-591 microcrystalline cellulose and carboxymethylcellulose sodium (DuPont-Nutrition & Biosciences, Wilmington, DE) and 2X Modified Eagle Medium (Temin’s modification, Gibco) supplemented with 2X antibiotic-antimycotic (Gibco), 2X Glutamax (Gibco) and 10% fetal bovine serum (Gibco). Plates were incubated at 37 °C and 5% CO₂ for 2 days. The monolayers were fixed with 10% neutral buffered formalin and stained with 0.2% aqueous Gentian Violet (RICCA Chemicals, Arlington, TX) in 10% neutral buffered formalin for 30 min, followed by rinsing and plaque counting. The half maximal inhibitory concentrations (IC50) were calculated using GraphPad Prism 8.

nLuc virus

Vero E6 cells (USAMRIID) were plated at 20,000 cells per well in black-walled 96-well plates (Corning 3904). mAbs were serially diluted 3-fold with a maximum of eight dilution spots. Diluted antibodies were mixed with 85 PFU/well of recombinant SARS-CoV-2-nLuc virus, and the mixtures were incubated at 37 °C with 5% CO₂ for 1 hour. Following incubation, growth media was removed, and virus-antibody mixtures were added to the cells in duplicate. Virus-only controls were included in each plate. Following infection, plates were incubated at 37 °C with 5% CO₂ for 48 hours. After the 48-hour incubation, cells were lysed, and luciferase activity was measured via Nano-Glo Luciferase Assay System (Promega) according to the manufacturer specifications. Neutralization titers were defined as the sample dilution at which a 50% reduction in relatively light unit (RLU) was observed relative to the average of the virus control wells.

Serum In Vitro Neutralization Assay

Aliquots of mNeonGreen reporter SARS-CoV-2 were pre-incubated for 1 hour in 5% CO₂ at 37 °C with serial 2-fold dilutions of serum and inoculated into Vero-E6 (ATCC catalog #CRL1586) triplicate monolayers in black polystyrene 96-well plates with clear bottoms (Corning). The final amount of virus was 200 PFU/well, serum was diluted with an initial 1:20 dilution followed by 2x fold dilutions. Cells were maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 10% FBS (HyClone) and 0.1% genaminic in 5% CO₂ at 37 °C. After 2 days of incubation, fluorescence intensity of infected cells was measured at a 488 nm wavelength using a Cytation 5 Cell Imaging Multi-Mode Reader (Biotek). The signal readout was normalized to virus control aliquots with no serum added and was presented as the percentage of neutralization.

In vitro live virus neutralization assays

50 µl of mNeonGreen reporter SARS-CoV-2 viruses were pre-incubated for 1 hour in 5% CO₂ at 37 °C with 50 µl of serial 4-fold dilutions of antibodies and inoculated into Vero-E6 (ATCC catalog #CRL-1586) triplicate monolayers in black polystyrene 96-well plates with clear bottoms (Corning). The final amount of virus was 200 PFU/well, initial concentration of antibodies was 200 µg/ml. Cells were maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 10% FBS (HyClone) and 0.1% genaminic in 5% CO₂ at 37 °C. After 2 days of incubation, fluorescence intensity of infected cells was measured at a 488 nm wavelength using a Cytation 7 Cell Imaging Multi-Mode Reader (Biotek). The signal readout was normalized to virus control aliquots with no antibodies added and was presented as the percentage of neutralization.

Viruses

The SARS-CoV-2 challenge strain used in this study is the first U.S. isolate SARS-CoV-2 USA-WAI-2020 from the Washington State patient.
identified on January 22, 2020\cite{1}. Passage 3 was obtained from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at UTMB. Virus stocks were propagated in Vero E6 cells. The challenge stock used in this study is passage 5. The recombinant SARS-CoV-2 expressing Neon Green protein (SARS-CoV-2-mNG) and its Spike protein mutants used in the neutralization assay was developed by Dr. Pei-Yong Shi at UTMB\cite{2,3}. Virus stocks were propagated in Vero E6 cells and a passage 1 was used in this study.

The alpha variant virus incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681R, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Beta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.

The Delta variant incorporates the following substitutions: Del 69-70, Del 144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, Del 69-70, D689-691, D950N; the deletion at positions 689-691 has not been observed in nature and was identified upon one passage of the virus. The Gamma variant incorporates the following substitutions: L18F, T1027I.
54. Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488.e4 (2021).
55. Cyrus Maher, M. et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. medRxiv https://doi.org/10.1101/2021.06.21.21259286 (2021).
56. Hinton, D. Emergency Use Authorization 094. FDA vol. 26 (2021).
57. Massacci, A. et al. Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. J. Transl. Med. 18, 1–7 (2020).
58. Zhou, H. X. Quantitative account of the enhanced affinity of the SARS-CoV-2 Spike for ACE2 caused by non-ACE2 binding mutations. Cell Host Microbe 27, 841–848.e3 (2020).
59. Tada, T. et al. Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv https://doi.org/10.1101/2021.02.18.431897 (2021).
60. De Gasparo, R. et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature 593, 424–428 (2021).
61. Li, Z. et al. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nat. Immuno. 23, 423–430 (2022).
62. Cho, H. et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci. Transl. Med. 13, eabi5413 (2021).
63. Ku, Z. et al. Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth. bioRxiv https://doi.org/10.1101/2022.02.01.478504 (2022).
64. Jones, B. E. et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv 1-29 https://doi.org/10.1101/2020.09.30.318972 (2020).
65. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
66. Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. 101, 2536–2541 (2004).
67. Sui, J. et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79, 5900–5906 (2005).
68. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009).
69. Tang, X. C. et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. 111, E2018–E2014 (2014).
70. Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).
71. Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020).
72. Beverly, L. J., Lockwood, W. W., Shah, P. P., Erdjument-Bromage, H. & Varmus, H. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc. Natl. Acad. Sci. USA 109, E19–E126 (2012).
73. Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146–1152 (2019).
74. Punjani, A., Rubinsteins, J. L., Fleet, D. J. & Brubaker, M. A. Cryo-PARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
75. Harcourt, J. et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 26, 1266–1273 (2020).
76. Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841–848.e3 (2020).
77. Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429–446.e14 (2020).

Acknowledgements
John Ludes Meyers cultured HEK293F cells and performed transfections for Ab 2-7 scFv. Sasha Dickinson provided technical assistance with grid loading and microscope operation for Ab 2-7 structure determination. SARS-CoV-2 S D614G used for the structure of Ab 2-7 was a kind gift from Florian Wurum (ExcellGene SA, Monthey, Switzerland). Sartorius kindly provided anti-human Fc (AHF) biosensors for the variant binding assay. The following reagents were obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, A.23.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55616; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, Theta Variant with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55633; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55615; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, Delta Variant with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55614; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.526 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55438; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55311; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.351 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55310; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, P.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55307; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells, NR-52724; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, D614G Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55343; Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, R.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55632; SARS-CoV Spike (S) Protein deltaTM, Recombinant from Baculovirus, NR-722; Human Embryonic Kidney Cells (HEK293) expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line, NR-52511.

WAM would like to acknowledge support from the Massachusetts Consortium on Pathogen Readiness (grant 290870.5116709.0016) and the National Institute of Allergy and Infectious Diseases (R01AI616152-01A1). EOS acknowledges support from INV-006133 from the COVID-19 Therapeutics Accelerator and the National Institute of Allergy and Infectious Diseases (IAID) U19 142790-S1. RSB acknowledges support from the National Institutes of Health (NIH) grant U54CA260543 and AI157155.

Author contributions
M.R.C. and W.A.M. designed the study and analyzed results. M.R.C., L.T., H.K., C.C., K.N., M.K., and Q.K.Z. identified, engineered, and characterized mAbs and bsAbs. N.K. and A.J.R. performed in vivo experiments in Syrian golden hamsters and in vitro experiments with VOCs. Y.J.H., L.V.T., R.J., and N.S. performed in vitro neutralization assays, A.S. and S.R.L. performed in vivo experiments in mice. POB generated cryo-EM structures of Ab 2-7 and EO generated cryo-EM structures for Ab12. A.H., G.A., A.B., R.S.B., A.G., J.S.M., E.O.S., and W.A.M. participated in experimental design and data analysis. M.R.C. and W.A.M. wrote the paper with all co-authors.
Competing interests
The authors declare no competing interests

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-33030-4.

Correspondence and requests for materials should be addressed to Wayne A. Marasco.

Peer review information Nature Communications thanks Christian Klein, Gabriel Lander, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022